This is a phase 1 study in which healthy volunteers will receive VIR-2482 or placebo and will be assessed for safety, pharmacokinetics, and immunogenicity of VIR-2482 in preventing Influenza A illness.

Inclusion Criteria:

• Healthy Male or Female age 18 to < 65 years
• Body mass index (BMI) of 18.0 kg/m^2 to 32.0kg/m^2

Exclusion Criteria:

• Any clinically significant chronic or acute medical condition that makes the volunteer unsuitable for participation
• History of influenza-like illness or confirmed influenza infection within 3 months prior to randomization.
• Fever-like illness within 5 days of randomization.
• History or clinical evidence of conditions considered high risk for developing influenza-related complications.